Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001818331-26-000041
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Total revenue | 102,254 | 87,115 |
| Cost of services | 34,043 | 28,639 |
| Gross profit | 68,211 | 58,476 |
| Research and development | 19,804 | 12,577 |
| Selling, general and administrative | 74,591 | 50,450 |
| Impairment loss | 31,287 | — |
| Loss from operations | (57,471) | (4,551) |
| Non-operating (expenses) income, net |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is GeneDx Holdings's R&D?
- GeneDx Holdings (WGS) reported R&D of $19.8M in Q1 2026.
- How has GeneDx Holdings's R&D changed year-over-year?
- GeneDx Holdings's R&D increased by 57.5% year-over-year, from $12.58M to $19.8M.
- What is the long-term trend for GeneDx Holdings's R&D?
- Over 4 years (2021 to 2025), GeneDx Holdings's R&D has grown at a -9.0% compound annual growth rate (CAGR), from $105.16M to $72.03M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about GeneDx Holdings's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude